Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Details
- Category: Clinical Trials
Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.
Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif
- Details
- Category: Bayer

Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care
- Details
- Category: Pfizer

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
- Details
- Category: Bristol-Myers Squibb

Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine
- Details
- Category: Boehringer Ingelheim

Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
- Details
- Category: Abbott

Teva Announces Approval of Generic Actonel®
- Details
- Category: Product

More Pharma News ...
- EPO Rules European Nexium® Process Patent Valid
- Aptivus® (tipranavir) capsules granted full approval by the U.S. FDA
- Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
- GSK seeks prequalification for Cervarix⢠from the World Health Organization
- Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome
- Pfizer Launches Independent Biotherapeutics and Bioinnovation Center
- Boehringer Ingelheim comments the nevirapine production for Rwanda by Apotex